Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

924.37 -13.07 (-1.39%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The Smartest Growth Stock to Buy With $100 Right Now
This beaten-down drugmaker is well positioned to turn things around. 
Via The Motley Fool
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Now may be the time to invest in drug companies, as they just slipped the tariff noose. 
Via The Motley Fool
Topics ETFs Government World Trade
Should You Buy Novo Nordisk Right Now?
The fallen pharma giant could make a big comeback in 2026. 
Via The Motley Fool
Should Investors Buy Eli Lilly Stock?
Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies. 
Via The Motley Fool
MarketBeat Week in Review – 10/06 - 10/10
Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data 
Via MarketBeat
Topics Economy
Smart Money Is Betting Big In LLY Options
 
Via Benzinga
Why Hims & Hers Health (HIMS) Stock Is Nosediving
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue... 
Via StockStory
Topics World Trade
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations
Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries. 
Via Benzinga
1 Vanguard ETF to Invest In That Can Turn $500 Monthly Into $800,000
This ETF has shown market-beating potential since its inception. 
Via The Motley Fool
Topics ETFs
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now
Ongoing developments make these companies look attractive. 
Via The Motley Fool
Topics Economy World Trade
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in... 
Via MarketMinute
Direxion's QQQU, QQQD ETFs Foster A Diversified Approach To Magnificent 7 Speculation
 
Via Benzinga
Topics ETFs
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest. 
Via MarketBeat
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Roche has a promising GLP-1 drug that is entering phase 3 trials. 
Via The Motley Fool
Amazon's Dual Thrust: Prime Discounts and Pharmacy Expansion Reshape Retail and Healthcare Landscapes
Amazon (NASDAQ: AMZN) continues to aggressively expand its strategic business developments, solidifying its e-commerce dominance through frequent Prime discount events and making significant inroads... 
Via MarketMinute
Topics Artificial Intelligence Economy
Recent Filing Shows That Rep. David Taylor Bought Over $5K Worth of Procter & Gamble Stock
 
Via Benzinga
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
These 2 AI Stocks Could Surpass Oracle in Market Cap by 2030
Investors should buy stakes in AI-powered stocks with scalable, asset-light business models. 
Via The Motley Fool
Topics Artificial Intelligence
Eli Lilly Stock Eases After-Hours: Ex-FDA Official Ejected By RFK Jr. Joins Firm — Will Investors Warm Up?
Investors reacted to the company’s leadership shake-up and new data from its ulcerative colitis therapy Omvoh showing sustained remission over four years. 
Via Stocktwits
Topics Government
Healthcare Sector Defies Broader Market Swings, Leads S&P 500 Momentum on October 7, 2025
On a day where the broader S&P 500 and Nasdaq Composite indices soared to new all-time record highs, the S&P 500 Healthcare sector presented a compelling, albeit nuanced, narrative of market leadership... 
Via MarketMinute
Topics Artificial Intelligence ETFs Intellectual Property
Looking At Eli Lilly's Recent Unusual Options Activity
 
Via Benzinga
Why QuidelOrtho (QDEL) Stock Is Down Today
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 4.4% in the morning session after Citigroup analyst Patrick Donnelly downgraded the stock to 'Neutral' from 'Buy' and lowered the... 
Via StockStory
Topics World Trade
Long-Term Study Shows Sustained Remission With Eli Lilly's Ulcerative Colitis Drug
Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ulcerative colitis patients. 
Via Benzinga
Where Will LLY Be in 5 Years?
After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030. 
Via The Motley Fool
Topics World Trade
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started. 
Via MarketBeat
Topics Government World Trade
$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Eli Lilly Eyes India For Manufacturing, Plans To Spend $1 Billion
Eli Lilly plans over $1 billion investment in India to expand drug manufacturing, partnerships, and a new Hyderabad facility. 
Via Benzinga
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief. 
Via MarketBeat
Topics Government Supply Chain World Trade
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.